Expanding Access to Ocular Gene Therapy
Recent milestones in inherited retinal disease (IRD) care highlight a rapidly evolving landscape of hope for patients and families. Among these developments, Ann & Robert H. Lurie Children’s Hospital of Chicago performed Illinois' first-ever gene therapy eye surgery using LUXTURNA (voretigene neparvovec-rzl). As the first FDA-approved directly administered gene therapy for a hereditary retinal degeneration, LUXTURNA targets biallelic RPE65 mutation-associated retinal dystrophy, a progressive condition that can lead to severe vision impairment and blindness.
By delivering a healthy, functioning copy of the RPE65 gene directly to retinal cells via subretinal injection, the treatment helps restore the visual cycle. This landmark surgery not only marks a crucial healthcare milestone for patients in the Midwest but also establishes Lurie Children's as a specialized treatment center equipped to handle advanced ocular interventions and future clinical trials.
Promising 24-Month Results in XLRP Gene Therapy Trials
While approved treatments like LUXTURNA pave the way for clinical care, ongoing research continues to target other devastating IRDs, such as X-linked retinitis pigmentosa (XLRP). XLRP is an aggressive inherited condition caused by mutations in the RPGR gene, primarily affecting males and frequently leading to blindness by middle age.
At recent ophthalmology congresses, researchers shared encouraging 24-month interim safety and efficacy data from the Phase 2 SKYLINE trial evaluating the investigational gene therapy laru-zova (AGTC-501). Designed to express the full-length RPGR protein to address photoreceptor damage, the therapy demonstrated a favorable safety profile with mostly mild-to-moderate, non-serious adverse events.
Crucially, the high-dose cohort achieved a 57% response rate in retinal sensitivity—measured via microperimetry—highlighting durable visual improvements over a two-year period. Experts note that these findings underscore the importance of identifying the optimal therapeutic window, as patients with preserved retinal anatomy and measurable baseline sensitivity experience the most pronounced benefits.
Shaping the Future of IRD Research and Treatment
These clinical updates underscore a broader paradigm shift in ophthalmology: genetic diagnoses are increasingly meeting actionable therapeutic solutions. Data from trials like SKYLINE continue to inform late-stage studies, such as the pivotal Phase 3 VISTA trial, moving the field closer to expanded treatment options for rare blinding conditions. For the IRD community, each successful surgical rollout and positive trial readout brings science one step closer to ensuring that inherited vision loss is no longer an inevitable outcome.